Testosterone is essential for alpha(2)-adrenoceptor-induced antinociception in the trigeminal region of the male rat.
Activation of the alpha(2)-adrenoceptor has been shown to produce antinociception. We have previously shown that the antinociceptive effect of clonidine, an alpha(2)-adrenoceptor agonist, is sex-specific and is abolished by exogenous estrogen in ovariectomized rats or high level of endogenous estrogen in proestrous females. Here, we investigated whether testosterone mediates the antinociceptive effect of clonidine in the trigeminal region of the male rat. Clonidine (7 microg/5 microl) was injected intracisternally through a PE-10 cannula implanted dorsal to the trigeminal region in orchidectomized (GDX) male Sprague-Dawley rats. In separate groups, testosterone propionate (250 microg/100 microl; GDX+T) or beta-estradiol benzoate (100 microg/100 microl; GDX+E) were injected subcutaneously 24 and 48 h respectively prior to the N-methyl-D-aspartic acid (NMDA)--or heat-evoked nociceptive test. NMDA-induced number of scratches or duration of scratching behavior did not change significantly in control groups with or without hormonal replacement. Clonidine significantly reduced both measures only in the GDX+T group but not in GDX or GDX+E group. Clonidine also significantly increased head withdrawal latency (HWL) in the GDX+T group, but not in GDX or GDX+E group. The antinociceptive effect of clonidine was reversed by yohimbine, an alpha(2)-adrenoceptor antagonist, in GDX+T group. We conclude that testosterone is required for the expression of antinociception produced by selective activation of the alpha(2)-adrenoceptor in the trigeminal region of the male rat. These findings further our understanding of sex-related differences in the modulation of nociception and may provide insight into development and administration of analgesic agents in young vs. aging men.
Nag
Subodh
S
Department of Neuroscience and Pharmacology, Meharry Medical College, Nashville, TN 37208, USA. snag@mmc.edu
Mokha
Sukhbir S
SS
D058669:Adrenergic alpha-2 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D002404:Catheterization; D003000:Clonidine / Q000494:pharmacology; D004958:Estradiol / Q000031:analogs & derivatives / Q000494:pharmacology; D004967:Estrogens / Q000494:pharmacology; D020249:Hormone Replacement Therapy; D006358:Hot Temperature; D008297:Male; D016202:N-Methylaspartate / Q000378:metabolism; D009919:Orchiectomy; D010146:Pain / Q000188:drug therapy / Q000378:metabolism*; D010147:Pain Measurement; D051381:Rats; D017207:Rats, Sprague-Dawley; D018341:Receptors, Adrenergic, alpha-2 / Q000378:metabolism*; D013739:Testosterone / Q000378:metabolism* / Q000494:pharmacology; D043343:Testosterone Propionate / Q000494:pharmacology; D013997:Time Factors; D014278:Trigeminal Nuclei / Q000187:drug effects / Q000378:metabolism*; D015016:Yohimbine / Q000494:pharmacology
D058669:Adrenergic alpha-2 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists; D004967:Estrogens; D018341:Receptors, Adrenergic, alpha-2; C074283:estradiol 3-benzoate; D015016:Yohimbine; D013739:Testosterone; D004958:Estradiol; D016202:N-Methylaspartate; D003000:Clonidine; D043343:Testosterone Propionate